Therefore, the aim of this study is to establish a radiomics-based model for predicting acquired EGFR T790M mutation in patients with advanced or metastatic NSCLC harbouring an EGFR-activating mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.